Klaria held its Annual General Meeting 2026
The meeting adopted 2025 financials, re-elected board members, and authorized a 20% share capital increase.
See the latest news and media coverage for Klaria. We track all announcements, press releases, and industry mentions in real time, all in one place.
Developer of transmucosal alginate film drugs
klaria.comLast updated
In short: Klaria secured a 25 MSEK bridge loan and finalized its 2025 financial reporting following a series of administrative delays.
The meeting adopted 2025 financials, re-elected board members, and authorized a 20% share capital increase.
R&D costs were 28.3 MSEK, loss after tax was -47.1 MSEK, and cash was 0.3 MSEK at year-end.
The agreement includes an option for an additional 15 MSEK (total 40 MSEK), supports global market access efforts, disburses immediately and runs until 2027-05-27.
The report shows net sales of 0.1 MSEK, R&D expenses of 4.9 MSEK, and a loss after tax of -8.7 MSEK.
kr 0.80 SEK 0.00-0.38% ...
The lending app is accused of targeting vulnerable borrowers with non-underwritten loans and predatory autopay.
Get access to full transcripts of current and past earnings calls to further evaluate Klaria Pharma Holding AB (KLAR:XSTO) stock's performance and strategic direction...
- Net sales 0.0 MSEK (0.0 MSEK) - Other income 0.0 MSEK (0.0 MSEK) - R&D expenses for the quarter amounted to 4.8 MSEK (9.3...
Track Klaria and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.